BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12407934)

  • 21. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Which collateral effects influence in the adherence with antipsychotic medication?].
    Lamela CA
    Vertex; 2002; 13 Suppl 1():31-9. PubMed ID: 12122426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long term--maximising potential for rehabilitation in patients with schizophrenia.
    Fagiolini A; Goracci A
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S123-9. PubMed ID: 17336767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Choosing an atypical antipsychotic.
    Sussman N
    Int Clin Psychopharmacol; 2002 Aug; 17 Suppl 3():S29-33. PubMed ID: 12570069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
    Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
    J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Extrapyramidal effects of antipsychotic drugs].
    Kulisevsky J; Otermin P
    Neurologia; 2003 Jun; 18(5):262-8. PubMed ID: 12768512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
    Mann K; Bartels M; Gärtner HJ; Schied HW; Wagner W; Heimann H
    Pharmacopsychiatry; 1987 Jul; 20(4):155-9. PubMed ID: 2886997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes.
    Dose M
    Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():3-13. PubMed ID: 11072761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of second generation antipsychotics on leptin and ghrelin.
    Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Three-dimensional ultrasonic movement analysis of gait and hand-movements in schizophrenic patients].
    Putzhammer A; Perfahl M; Pfeiff L; Müller JL
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S38-42. PubMed ID: 15818519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.
    Kane JM; Woerner M; Sarantakos S
    J Clin Psychiatry; 1986 May; 47 Suppl():30-3. PubMed ID: 2871014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Body weight increase: a side effect of zotepin (Nipolept)?].
    Wetterling T; Müssigbrodt H
    Nervenarzt; 1996 Mar; 67(3):256-61. PubMed ID: 8901286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of side effects caused by typical antipsychotics.
    Arana GW
    J Clin Psychiatry; 2000; 61 Suppl 8():5-11; discussion 12-3. PubMed ID: 10811237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapyramidal side effects: a historical perspective.
    Rifkin A
    J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.